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Introduction
Lung cancer is the leading cause of  cancer-related deaths 
in the United States (1). Among all treatment options for 
non-small-cell lung cancer, stereotactic radiosurgery with 
systems such as CyberKnife® is emerging as a possibility 
for patients who are medically unfit to undergo lung-tumor 
resection or for those whose tumor is unresectable. For pre-
cise tumor ablation, the CyberKnife® system may require 
fiducial marker placement in or near the target tumor (2). 
Placing these reference points may lead to several complica-
tions, such as pneumothorax (3) and hemorrhage (4). In this 
case study, we report a complication not previously de-
scribed: the appearance of  new metastatic focus in the area 
of  the fiducial marker placement. 
Case report
   A 65-year-old male with a 100-pack-year smoking history 
initially presented with increasing shortness of  breath. A 
chest CT showed a partially cystic right-upper-lobe lung 
nodule measuring 1.1 by 1.3 cm (Fig. 1A). A CT-guided 
biopsy confirmed non-small-cell lung carcinoma. PET/CT 
for staging showed hypermetabolic activity at the site of  the 
nodule in the right upper lobe with SUV (max) of  3.8 
without additional evidence of  disease (Fig. 1B). The pa-
tient was staged T1N0M0 and was not a candidate for sur-
gical resection secondary to COPD and a FEV1 less than 
30%. The patient was treated with a combination of  che-
moradiation and completed 6300 cGy to the right upper 
lobe. At the three-month followup, PET/CT showed a 
slight progression of  the right upper lobe tumor, with SUV 
(max) 2.8 but a size of  1.8 by 1.3 centimeters. However, six 
months later, a new CT showed enlargement of  the known 
cancerous area to 2.3 by 4.3 centimeters; repeated PET/
CT 3 days later showed an SUV (max) of  8.7 (Fig. 2). 
It was decided that stereotactic body radiotherapy with 
CyberKnife would be a superior alternative to re-
irradiation with conventional external-beam technique. 
We therefore placed a CT-guided gold fiducial marker. 
Initially, a 17G-by-6cm guide needle was advanced into the 
lesion. We made three passes using a 20G-by-11cm Temno 
biopsy needle, and confirmed the needle position using CT 
imaging. We then advanced the guide needle through the 
lesion to the deepest, most medial part of  the tumor, and 
placed a single set of  coupled gold fiducial markers (0.8 x 
1.0 cm Civco®, Orange City, Iowa) (Fig. 3A). We then 
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made a second pleural puncture parallel to the first punc-
ture, 3 cm cephalad. We advanced a 17G-by-6cm guide 
needle into the lung, inferior to the cavitary portion of  the 
abnormality and deep to it. We placed an additional set of  
coupled fiducial markers at this location (Fig. 3B). 
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Figure 3: CT-guided biopsy and fiducial marker placement. A. Sin-
gle set of coupled gold fiducial markers were placed in the deepest 
part of the mass, passing though the malignant tissue in the axial 
plane. An additional set of coupled fiducial markers was placed in 
the lung adjacent to the most cephalad aspect of the cavitary por-
tion of the abnormality and deep to it. Technique: Siemens 64-slice 
CT scanner, 120 kV, 250 mAs, 5mm sections, non-contrast scan 
during fiducial marker placement. B. Single set of coupled gold 
fiducial markers were placed in the deepest part of the mass, pass-
ing though the malignant tissue in the axial plane. An additional set 
of coupled fiducial markers was placed in the lung adjacent to the 
most cephalad aspect of the cavitary portion of the abnormality and 
deep to it (arrow). Technique: Siemens 64-slice CT scanner, 120 
kV, 250 mAs, 5mm sections, noncontrast scan during fiducial 
marker placement.
Figure 1: A. 65-year-old male with small cell lung cancer. A. Right-
upper-lobe lung nodule on axial lung windows of initial chest CT. 
Irregularly shaped peripheral nodule measures 1.1 by 1.3 cm. 
Technique: Siemens 64-slice CT scanner, 120 kV, 250 mAs, 5mm 
sections, noncontrast scan. B. PET/CT for staging showed hyper-
metabolic activity (SUV [max] 3.8) at the site of the nodule in the 
right upper lobe, axial plane (arrow). Technique: Scan was per-
formed 60 minutes after injection of 12-16 mCi of FDG tracer, with 
the following parameters: Siemens 64-slice CT scanner 120 kVp, 
250mAs, 5-mm slice thickness, and CT-based attenuation correc-
tion algorithm using two iterations and 8 subsets.
Figure 2: Right-upper-lobe lesion. PET/CT showed a definite pro-
gression of the right-upper-lobe tumor, with the mass now measur-
ing 2.3 by 4.3 centimeters with a SUV (max) of 8.7. Technique: 
Scan was performed 60 minutes after injection of 12-16 mCi of 
FDG tracer, with these parameters: Siemens 64-slice CT scanner, 
axial plane, 120 kVp, 250mAs, 5mm slice thickness, and CT-based 
attenuation correction algorithm using two iterations and 8 subsets.
Immediate postprocedure images displayed mild paren-
chymal hemorrhage at the inferior fiducial placement site. 
No pneumothorax was identified on a followup chest ra-
diograph. Following the fiducial placement, the patient 
completed stereotactic body radiotherapy to the right up-
per lobe. He received 6000 cGy in three fractions of  2000 
cGy each. Followup CT three months after the marker 
placement indicated that the primary mass remained stable 
in size. However, it also showed a small, 0.7cm nodule di-
rectly adjacent to the more medially located fiducial 
marker that was not present on prior studies (Fig. 4). 
Followup PET/CT (Fig. 5A) demonstrated the dominant 
lesion to be less FDG-avid than in the previous study. The 
new, smaller 0.72cm lesion adjacent to the medially located 
fiducial marker showed increased metabolic activity and 
interval growth (Fig. 5B). 
A presumptive diagnosis of  tumor progression at the site 
of  fiducial marker was made. The new lesion was not biop-
sied, and further treatment continued with the current 
markers (Fig. 6).
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Figure 4: After fiducial placement and subsequent stereotactic 
radiosurgery. CT scan shows fiducial marker is in place (original 
mass at red arrow; new mass with adjacent fiducial at blue arrow) 
and around it is now a new 7.2 mm foci of disease, just medial to 
the marker. Technique: Siemens 64-slice CT scanner, 120 kV, 250 
mAs, 5mm sections, non-contrast scan. A: Axial. B: Coronal refor-
mat. C: Sagittal reformat. 
Figure 5: Followup PET/CT (A) and PET only (B) demonstrated the 
dominant lesion to be less glucose-avid (slightly out of plane). The 
new, smaller lesion adjacent to the medially located fiducial marker 
showed increased metabolic activity and interval growth in the axial 
plane. (Fiducial marker is obscured by metabolic activity.) Tech-
nique: Scan was performed 60 minutes after injection of 12-16 mCi 
of FDG tracer, with the following parameters: Siemens 64 slice CT 
scanner, 120 kVp, 250mAs, 5-mm slice thickness, and CT-based 
attenuation correction algorithm using two iterations and 8 subsets.
Discussion
Non-small-cell lung cancer is thought to occur secondary 
to repeated assaults on the lung tissue. It occurs in over 1.2 
million individuals a year, 160,000 of  whom are in the 
United States. It has a slight male predilection, which may 
be due to a higher percentage of  male smokers than female 
smokers in past decades. The average age at diagnosis is 
around 70 years, and affected individuals often have to-
bacco, radon, and asbestos or particulate-matter exposures. 
Patients typically present with cough, and may have he-
moptysis depending on the location of  the lesion. Chest 
radiography may reveal a solitary pulmonary nodule, mass, 
pleural effusion, lung collapse, or mediastinal or hilar full-
ness. CT of  the chest shows in greater detail the size, loca-
tion, and extent of  primary tumor and evaluates for hilar 
and/or mediastinal lymphadenopathy and distant metasta-
ses within the thoracic region. Transbronchial ultrasound 
may theoretically be used for diagnosis, but is not used 
commonly in practice. The main form of  treatment is sur-
gical resection with adjuvant chemotherapy and radiation. 
The prognosis varies based on the size of  the tumor, the 
presence of  metastasis, and the severity of  the patient’s 
symptoms, but overall prognosis is poor. Furthermore, 
many patients have poor lung function, making resection 
next to impossible. Stereotactic radiosurgery systems such 
as CyberKnife® are emerging as a possibility for patients 
who are unable to undergo lung-tumor resection or who 
have unresectable disease. 
The CyberKnife® stereotactic radiosurgery system is a 
frameless, image-guided device with a 6-megavolt linear 
accelerator. This is mounted on a robotic arm to administer 
radiation to a tumor from different trajectories while mini-
mizing dosage to adjacent normal tissue. It is emerging as a 
new option for patients with unresectable disease and is an 
effective treatment for non-small-cell lung cancer. Further-
more, it avoids the need for breath holding because it com-
pensates for changes in tumor position during the normal 
respiratory cycle, which in patients with severe lung disease 
can be an issue. In stereotactic radiotherapy and radiosur-
gical systems such as CyberKnife®, fiducial markers are 
necessary to allow precise tumor targeting. Complications 
of  fiducial marker placement include pneumothorax (most 
common), hemorrhage, hemoptysis, and fiducial marker 
migration. 
We present a case of  what we believe to be tumor-track 
seeding secondary to fiducial placement, with subsequent 
formation of  a new metastatic focus. We hypothesize that 
the placement of  the fiducial marker through the original 
tumor may have led to seeding of  malignant cells at the 
very end of  the track, leading to the development of  a new 
tumor nodule around the gold fiducial marker. Although 
(to the best of  our knowledge) no current literature has 
mentioned this as a possible complication of  fiducial 
marker placement, we believe that the second metastatic 
focus was due to a collection of  tumor cells by the tip of  
the fidicial marker insertion instrument, which on its inser-
tion and/or removal deposited these cells at the end of  its 
path. We have arrived at our conclusion based on the simi-
larity of  the technique used for transthoracic needle biopsy 
and transthoracic fiducial placement. Although a rare 
complication of  needle biopsies, tumor seeding of  the pleu-
ral space and the skin has been reported. However, when 
disseminated through the needle tract, malignant cells 
rarely mature into tumor masses, as it is generally believed 
that most lung cancer cells have a low potential to grow in 
the pleural space. Indeed, Tomiyama et al surveyed 9,783 
lung biopsies and found only 6 cases (0.061%) of  tumor 
seeding at the site of  the biopsy route (5). Overall, the inci-
dence of  tumor seeding leading to the formation of  metas-
tasis has been reported to be less than 1% (6), but a study 
from Sawabata has shown that fine-needle aspiration leads 
to spread of  malignant cells in 60% of  cases (7). In this 
paper, the development of  new foci of  disease at the site of  
the track was not explored, however. Furthermore, it has 
been suggested that the risk of  tumor implantation depends 
on track size. Therefore, the use of  large-bore needles or 
thoracopscopy ports potentially carries a relatively higher 
risk of  tumor seeding (6). 
Although tumor seeding may be common, implantation 
metastasis is rare and should not be a contraindication to 
fiducial marker placement. Creation of  a new foci of  dis-
ease maybe a rare but serious complication of  fiducial 
marker placement when placement involves going through 
the tumor focus. Hence, current techniques for the inser-
tion of  fiducial markers may want to consider a peripheral 
approach to the tumor if  possible to avoid tracking of  ma-
lignant cells and the possibility of  the formation of  new 
disease foci. 
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